On Tuesday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) opened lower -8.00% from the last session, before settling in for the closing price of $14.38. Price fluctuations for CNTA have ranged from $7.75 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. Company’s average yearly earnings per share was noted 29.13% at the time writing. With a float of $80.34 million, this company’s outstanding shares have now reached $132.63 million.
Let’s determine the extent of company efficiency that accounts for 77 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Centessa Pharmaceuticals plc ADR is 39.43%, while institutional ownership is 54.79%. The most recent insider transaction that took place on Mar 25 ’25, was worth 163,386. In this transaction Chief Business Officer of this company sold 10,000 shares at a rate of $16.34, taking the stock ownership to the 134,021 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Officer proposed sale 10,000 for $16.53, making the entire transaction worth $165,300.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.48% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Check out the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). In the past quarter, the stock posted a quick ratio of 9.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Looking closely at Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA), its last 5-days average volume was 1.21 million, which is a jump from its year-to-date volume of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 15.59%. Additionally, its Average True Range was 1.13.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 3.62%, which indicates a significant decrease from 4.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.94% in the past 14 days, which was lower than the 60.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.38, while its 200-day Moving Average is $14.70. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $14.04. Second resistance stands at $14.86. The third major resistance level sits at $15.37. If the price goes on to break the first support level at $12.71, it is likely to go to the next support level at $12.20. Now, if the price goes above the second support level, the third support stands at $11.38.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
There are currently 133,184K shares outstanding in the company with a market cap of 1.75 billion. Presently, the company’s annual sales total 0 K according to its annual income of -235,760 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -111,330 K.
